Skip to main content
. 2023 Apr 26;28(7):644–e564. doi: 10.1093/oncolo/oyad106
Primary Assessment method: Objective Response Rate
Number of patients screened 11
Number of patients enrolled 9
Number of patients evaluable for toxicity 9
Number of patients evaluated for efficacy 9
Evaluation method RECIST 1.1
Response assessment, CR 0 (0%)
Response assessment, PR 0 (0%)
Response assessment, SD 1 (11.1%)
Response assessment, PD 8 (88.9%)
Median duration assessment, PFS 1.9 months
Median duration assessment, OS 5.3 months